Peptimmune, Inc. Secures $20,400,000 Series C Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=267458cf-8443-40e7-b221-f1eec209b9d2&Preview=1 -
Date
7/15/2005 -
Company Name
Peptimmune, Inc. -
Mailing Address
64 Sidney Street Cambridge, MA 02139 -
Company Description
Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. -
Website
http://www.peptimmune.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,400,000 -
Transaction Round
Series C -
Proceeds Purposes
The proceeds of the financing are being used to advance clinical development of Peptimmune’s autoimmune and metabolic disease programs -
M&A Terms
-
Venture Investor
New Enterprise Associates -
Venture Investor
MPM Capital -
Venture Investor
Prism VentureWorks -
Venture Investor
Vanguard Ventures -
Venture Investor
Hunt Ventures -
Venture Investor
Silicon Valley Bank -
Venture Investor
Itochu Corporation
